A consortium of scientists and doctors


image: A consortium of scientists and doctors collaborate to define the new field of longevity medicine
seen Following

Credit: Deep Longevity Limited

Wednesday December 8, 2021 – As described in the recent Lancet Healthy Longevity article titled “Longevity medicine: improving the skills of the doctors of tomorrowFor the longevity biotechnology industry to emerge, physicians need to be updated on recent advances in aging research, diagnostic techniques and clinical trial management. Recently the group released a book chapter titled AI in longevity medicine describing the fundamental aspects of this emerging field.

Today, a group of scientists and physicians including scientists from Deep Longevity, a company primarily engaged in the development of explainable artificial intelligence systems to track aging rates at multiple levels, announced a research collaboration and the launch of Longevity Medicine 201, an extended longevity medicine course for physicians (www.longevity.degré). This is the second course in the series of Longevity Medicine courses, the first being the 2.5-hour Longevity Medicine 101 course, An Introduction to Longevity Medicine for Physicians which is already available at multiple platforms and received CME accreditation in August 2021.

The first course in the series, the CME-accredited 2.5-Hour Longevity Medicine 101 Introductory Course launched in December 2020 and became an instant sensation with over 2,500 healthcare professionals attending. registering on multiple platforms. It was originally developed by a group of physicians and scientists to facilitate the adoption of biomarkers of aging and longevity, as well as the latest advances in aging research in the medical community. An expanded team of several volunteer physicians, medical students and scientists are working to expand the availability of longevity medicine education.

Aimed at healthcare professionals and students, the Longevity Medicine 201 course is intended to be a comprehensive, well-structured and reliable resource. It contains a core 200-slide course curriculum offering an introduction to the field, course slides, lecture notes, quizzes, guest lectures, as well as references to additional reading material and online resources. . AI technology was used to narrate the Longevity Medicine 201 course because it is easy to re-narrate and edit as new content becomes available. The course incorporates the latest advances in AI in healthcare and aging research and democratizes access to long-term care.

“Over the past decade, many technologies, including artificial intelligence and research on aging, have converged, allowing the emergence of a new scientific and medical field: longevity medicine. Longevity medicine goes beyond traditional preventive medicine which aims to prevent disease and rather aims to maintain the patient at the age of optimal performance in the context of the entire lifespan. The Longevity Medicine course is designed to bridge the gap between laboratory science and medicine, provide an update on the latest advances in aging research and AI, and prepare physicians for the new type. clinical trials and patient management, ”said Alex Zhavoronkov, PhD. , co-founder of the Longevity Medicine course and Chief Longevity Officer at Deep Longevity.

“Longevity medicine is a symbiosis of AI and HI which allows trajectories to be drawn from a multitude of very heterogeneous, longitudinal and multidimensional data on each patient at a precise moment, creating a digital extension health care. There is a gap between developments in the science of longevity medicine – gerosciences, biogerontology, omics, AI, imaging – and the clinic. It is only through a collaborative effort that physicians can be offered a course of study, then apply the knowledge to bridge this gap and implement diagnostic and therapeutic approaches in the clinic, ”a said Evelyne Bischof, MD, MPH, doctor of longevity, co-founder of the course.

“Aging is the greatest risk factor for most diseases. Clearly, the ability of physicians to target aging will become increasingly important as the population ages. Longevity medicine is fundamentally personalized preventive medicine and should be at the heart of all modern medical education. We have new evidence that we can increase healthy aging and delay age-related diseases. As physicians, it is our sworn duty to reduce suffering, and longevity medicine will become essential in keeping the elderly free from disease for as long as possible. Said Morten Scheibye-Knudsen, MD, PhD, associate professor, University of Copenhagen.

“Modern geroscience has accumulated a rich arsenal of knowledge on the mechanisms of aging and approaches to prolong the active period of life. This also applies to practical things like daily diet, diet, exercise, goprotectors, and biomarkers of aging. In addition, there are tools to manage your longevity (diagnostics + recommendations). This is what our course is, aimed at the widest audience of doctors interested in the prevention of age-related diseases, ”said Professor Alexey Moskalev, corresponding member of the Russian Academy of Sciences, he is a member Editorial boards of Aging research journals, aging, biogerontology, frontiers in genetics of aging, aging and diseases, journals and reports on stem cells, gerontology, advances in gerontology.

About deep longevity

Deep Longevity is a wholly owned subsidiary of Endurance Longevity (SEHK:0575.HK), a publicly traded company. Deep Longevity develops explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organic, systemic, physiological and psychological levels. He is also developing systems for the emerging field of longevity medicine that allow physicians to make better decisions about interventions that may slow or reverse aging processes. Deep Longevity has developed the Longevity as a Service (LaaS) © solution to integrate several deep aging biomarkers called “deep aging clocks” to provide a universal multifactor measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity began its independent journey in 2020 after securing funding from the most credible venture capital firms specializing in biotechnology, longevity and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, Oculus co-founder, Michael Antonov, and other AI and biotech investors have supported the company. Deep Longevity has established a research partnership with one of the world’s premier longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.


About endurance longevity (stock code: 0575.HK)

Endurance Longevity is a diversified Hong Kong-based investment group currently holding various corporate and strategic investments focused on the health, wellness and life sciences sectors. The Group has a strong investment history and has returned approximately US $ 298 million to its shareholders in the 21 years of financial reporting since its IPO.


Source link


Comments are closed.